For clinical investigational sites on an EDC trial, which of the following archival options allows traceability of changes made to data?
Correct Answer: D
Regulatory agencies such as the FDA and ICH require that electronic data be retained in a format that preserves audit trails and traceability. While PDF images (option C) provide a static representation of data, they do not preserve the underlying audit trail (i.e., who changed what, when, and why). The ASCII data files with corresponding audit trails (option D) provide complete transparency and comply with 21 CFR Part 11 and GCDMP archival standards. Option A (storing computers) is unnecessary and impractical, and Option B (paper source documents) are site records, not system archives. Hence, option D is correct - ASCII data files with audit trails meet traceability and compliance standards. Reference (CCDM-Verified Sources): SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 - Archival Formats and Audit Trail Retention ICH E6(R2) GCP, Section 5.5.3 - Data Integrity, Audit Trails, and Record Retention FDA 21 CFR Part 11 - Electronic Records; Audit Trail and Retention Requirements
Question 7
Which of the following data verification checks would most likely be included in a manual or visual data review step?
Correct Answer: B
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks. According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks-such as verifying adverse event treatments against concomitant medication records-require clinical judgment and contextual understanding. For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Verification Principles
Question 8
What significant difference is there in the DM role when utilizing an EDC application?
Correct Answer: A
The most significant difference in the Data Manager's role when using an Electronic Data Capture (EDC) system is that data updates are implemented directly by site personnel (Option A). According to the GCDMP (Chapter: Electronic Data Capture Systems), EDC technology shifts responsibility for data entry and correction from the sponsor or CRO to the investigator site, enabling real-time data entry and validation. This eliminates the need for double entry or remote data transcription, allowing Data Managers to focus on system validation, query management, and data quality oversight rather than physical data handling. However, the EDC system still requires full validation (contrary to Option B). Metrics generation (Option C) and CRF tracking (Option D) are important but not unique to EDC-based workflows. Thus, the correct answer is Option A - Data updates are implemented by the sites, reflecting the most fundamental operational shift introduced by EDC systems. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 4.1 - Role of the Data Manager in EDC ICH E6 (R2) GCP, Section 5.5.3 - Electronic Data Entry and Responsibilities FDA 21 CFR Part 11 - Electronic Records and Signatures: Data Entry Responsibilities
Question 9
A study numbers subjects sequentially within each site and does not reuse site numbers. Which information is required when joining data across tables?
Correct Answer: A
When subjects are numbered sequentially within each site, it means that the subject identification numbers (Subject IDs) restart from 001 at each site. For example, Site 101 may have Subject 001, and Site 102 may also have a Subject 001. In such cases, the subject number alone is not globally unique across the entire study. Therefore, when integrating or joining data across multiple database tables (for example, linking demographic, adverse event, and laboratory data), both the site number and the subject number are required to create a unique key that accurately identifies each record. According to the Good Clinical Data Management Practices (GCDMP, Chapter on CRF Design and Data Collection), every data record in a clinical trial database must be uniquely and unambiguously identified. This is typically achieved through a composite key, combining identifiers such as site number, subject number, and sometimes study number. The GCDMP specifies that a robust data structure must prevent duplication or mislinking of records across domains or tables. Furthermore, FDA and CDISC standards (SDTM model) also emphasize the importance of unique subject identifiers (USUBJID), which are derived from concatenating the study ID, site ID, and subject ID. This ensures traceability, integrity, and accuracy of subject-level data during database joins, data exports, and regulatory submissions. Thus, in the described scenario, since subject numbering restarts at each site, both the site number and subject number are required to uniquely identify and correctly join subject data across different datasets or tables. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.1 - Unique Subject Identification CDISC SDTM Implementation Guide, Section 5.2 - Subject and Site Identification (Variable: USUBJID) FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Data Integrity and Record Identification
Question 10
According to ICH E6, developing a Monitoring Plan is the responsibility of whom?
Correct Answer: A
According to ICH E6(R2) Good Clinical Practice (GCP), Section 5.18.1, the Sponsor is ultimately responsible for developing and implementing the Monitoring Plan. The Monitoring Plan defines: The extent and nature of monitoring (e.g., on-site, remote, risk-based). The responsibilities of monitors. The communication and escalation procedures for data quality and protocol compliance. While the CRO (B) or Monitor (D) may perform monitoring activities under delegation, the Sponsor retains legal accountability for ensuring a compliant and effective plan is developed and maintained. The Data Manager (C) may contribute by outlining data review workflows, but is not responsible for authoring or owning the plan. Therefore, option A (Sponsor) is the correct answer. Reference (CCDM-Verified Sources): ICH E6(R2) GCP, Section 5.18.1 - Purpose and Responsibilities for Monitoring SCDM GCDMP, Chapter: Regulatory Compliance and Oversight, Section 5.3 - Sponsor Responsibilities in Monitoring and Quality Assurance FDA Guidance for Industry: Oversight of Clinical Investigations - Sponsor Responsibilities (2013)
